UnitedHealth Group (UNH) shares surged more than 5% in early trading Thursday after two major Wall Street firms signaled optimism about the health insurer's outlook, pointing to signs that medical costs are stabilizing. Bank of America upgraded the stock to Buy from Neutral and raised its price target to $450 from $420, while Morgan Stanley increased its target to $453 from $395, maintaining an Overweight rating.
The moves reflect growing confidence that the first-quarter improvement in medical cost trends was not merely a temporary blip caused by a mild flu season and adverse weather. Bank of America analyst Kevin Fischbeck noted that recent data make it "more difficult to believe" that the first-quarter performance was solely due to those factors, according to TipRanks. The stock had fallen for five consecutive sessions before Thursday's rally.
Morgan Stanley's Erin Wright highlighted that managed-care stocks have been "grinding higher" amid signs of softer utilization, or how often patients seek medical care. She also pointed to potential artificial intelligence-driven savings across the sector, which could boost both revenue and cost efficiency. The broader managed-care group benefited from the sentiment, with Elevance Health, Cigna, and Humana all posting gains.
UnitedHealth shares traded at around $398 as of 10 a.m. in New York, up 5.7% on the day. Year to date, the stock has gained approximately 21%. The average analyst price target stands at roughly $404, tighter to current levels than the more bullish calls from BofA and Morgan Stanley.
UnitedHealth continues to position itself as a turnaround story rather than a pure growth play. The company reported first-quarter revenue of $111.7 billion, a 2% increase, with adjusted earnings per share of $7.23. In April, management raised its 2026 adjusted earnings guidance to above $18.25 per share. CEO Stephen Hemsley emphasized a focus on affordability, transparency, and better-connected care.
The board also approved a quarterly dividend of $2.32 per share for shareholders of record on June 15, payable June 23, up from the $2.21 paid in the first quarter.
Additional bullish calls have emerged in recent weeks. On May 27, Bernstein raised its price target to $492 from $444, and Barclays increased its target to $429 from $373, both maintaining positive ratings. UnitedHealth also appeared in a list of "safe" long-term stocks with 130 hedge fund holders, as noted by Insider Monkey.
However, risks remain. On May 29, Massachusetts filed a lawsuit against UnitedHealth's insurance arm, alleging it defrauded the state's Medicaid system of over $100 million through "upcoding," a practice of making diagnoses appear more severe to increase payments. UnitedHealth has called the lawsuit "meritless."
For now, traders are focusing more on claims trends than legal challenges. But analysts caution that if medical utilization rises in June or July, or if regulatory actions intensify, the new price targets could prove less of a floor and more of a hurdle for a company still working to rebuild trust.
